- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00240084
Nesiritide and Vo2 Max in Heart Failure Patients
June 17, 2013 updated by: Leway Chen, University of Rochester
This research study, funded by Scios, Inc., and conducted by the Cardiology Division of the Department of Medicine at the University of Rochester School of Medicine and Dentistry investigates the potential benefit of nesiritide (brand name is Natrecor(TM))in improving exercise capacity in patients with heart failure (HF).
Previous studies have shown beneficial hemodynamic and neurohumoral effects of nesiritide infusion in the therapy of decompensated heart failure.
Other studies have demonstrated increases in endogenous BNP levels (normalized for exercise workload) in HF patients during and after exercise.
However, trials involving the measurement of exercise capacity in this population following BNP administration are lacking.
This is an experimental prospective, non-blinded, pilot study with a sample size of 20 patients, all serving as their own controls.
This study involves off-label use of the drug nesiritide (indicated for IV treatment of NYHA Class II and III patients, and this study is enrolling Class II and III patients) and has received FDA approval, and an IND.
Subjects are recruited from the population of referrals to the Strong Memorial Hospital Heart Failure and Transplantation clinical service, who meet all the inclusion criteria and none of the exclusion criteria may participate in the study.
Enrolled study subjects perform an exercise VO2 max test, receive a 24 hour infusion of nesiritide and perform a second exercise VO2 max test.
Study Overview
Detailed Description
See above comments.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 18-65 with NYHA Class II or III heart failure
- Referred to Strong Memorial Hospital for consideration of heart transplant
- Male or female and infertile or using effective contraception with negative pregnancy test
- Capable of IV access
- Able to perform a maximal bicycle test and tolerate mouthpiece and nose clip
- Fully understands and has signed Informed Consent Form before study begins
- Endogenous BNP level of at least 100 pg/mL
- Current smokers smoking < 3 cigarettes / day. Smoking is not permitted within the hospital, ergo subjects would not be permitted to smoke during study participation.
Exclusion Criteria:
- NYHA Class i or IV heart failure
- Creatinine clearance < 30 ml/min, as determined within 2 weeks of the start of the study
- EF > 40%
- Evidence of primary lung disease
- Hypersensitivity to nesiritide or any of its' components
- Current smokers as defined by > 3 cigarettes / day
- Stroke within 3 months, myocardial infarction within 2 months, or any evidence of active myocardial ischemia
- Unwillingness ir inability to remain in the hospital overnight
- Clinical condition or laboratory abnormality which may increase risks associated with participation or interfere with result interpretation
- Any condition which would preclude heart transplantation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nesiritide infusion
Single arm study.
24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.
|
administration of IV nesiritide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak VO2
Time Frame: 24 hours
|
The goal of this study is to determine whether a continuous 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute will produce a significant improvement in exercise capacity as defined by maximum oxygen consumption (VO2 peak).
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Leway Chen, MD, University of Rochester
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Primary Completion (Actual)
November 1, 2005
Study Completion (Actual)
November 1, 2005
Study Registration Dates
First Submitted
October 13, 2005
First Submitted That Met QC Criteria
October 13, 2005
First Posted (Estimate)
October 17, 2005
Study Record Updates
Last Update Posted (Estimate)
June 19, 2013
Last Update Submitted That Met QC Criteria
June 17, 2013
Last Verified
June 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NES V02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
Clinical Trials on nesiritide (Natrecor(TM))
-
Mayo ClinicNational Institutes of Health (NIH)Completed
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsCompletedLeft Ventricular Diastolic DysfunctionUnited States
-
Scios, Inc.CompletedCardiomyopathies | Heart Failure, Congestive | Dyspnea, Paroxysma
-
Brigham and Women's HospitalScios, Inc.CompletedRenal Insufficiency | Congestive Heart FailureUnited States
-
University of Medicine and Dentistry of New JerseyScios, Inc.WithdrawnPulmonary Edema | Dyspnea | Heart Failure, CongestiveUnited States
-
University of California, Los AngelesScios, Inc.Completed
-
M.D. Anderson Cancer CenterTerminatedHeart Failure | Cardiovascular Disease | Heart Disease | Congestive Heart Failure | Acute Heart Failure | Diastolic Heart Failure
-
Emory UniversityScios, Inc.Terminated
-
M.D. Anderson Cancer CenterTerminatedCancer | Pulmonary Hypertension | Lung Disease | Cardiothoracic SurgeryUnited States
-
Virginia Commonwealth UniversityTerminatedCongestive Heart Failure | Cardiorenal SyndromeUnited States